Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Cheng, Allen C.; Turnidge, John; Collignon, Peter; Looke, David; Barton, Mary; Gottlieb, Thomas

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Published Date:

Sep 2012

Source:

Emerg Infect Dis. 18(9):1453-1460.

[PDF-229.98 KB]

Details:

Personal Authors:

Cheng, Allen C. ; Turnidge, John ; Collignon, Peter ; Looke, David ; Barton, Mary ; ... More ▼

Keywords:

[+]

Description:

Fluoroquinolone antimicrobial drugs are highly bioavailable, broad-spectrum agents with activity against gram-negative pathogens, especially those resistant to other classes of antimicrobial drugs. Australia has restricted the use of quinolones in humans through its national pharmaceutical subsidy scheme; and, through regulation, has not permitted the use of quinolones in food-producing animals. As a consequence, resistance to fluoroquinolones in the community has been slow to emerge and has remained at low levels in key pathogens, such as Escherichia coli. In contrast to policies in most other countries, this policy has successfully preserved the utility of this class of antimicrobial drugs for treatment of most infections.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Supporting Files:

	11-1515-F1.gif	image/gif
	11-1515-F1.jpg	image/jpeg
	11-1515-F2.gif	image/gif
	11-1515-F2.jpg	image/jpeg
	11-1515.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

Antimicrobial Drug Resistance, Regulation, and Research1

Personal Author:

Metlay, Joshua P.; Powers, John H.; Dudley, Michael N.; Christiansen, Keryn; Finch, Roger G.;

Corporate Author:

on behalf of the Second Colloquium of the International Forum on Antibiotic Resistance

Published:

Feb 2006

Source:

Emerg Infect Dis. 12(2):183-190.

Description:

Innovative regulatory and legislative measures to stimulate and facilitate the development of new antimicrobial drugs are needed. We discuss research approaches that can aid regulatory decision making on the treatment of resistant infections and mini...

File Type:

[PDF - 258.75 KB]
Campylobacter Antimicrobial Drug Resistance among Humans, Broiler Chickens, and Pigs, France

Personal Author:

Gallay, Anne; Prouzet-Mauléon, Valérie; Kempf, Isabelle; Lehours, Philippe; Labadi, Leila; Camou, Christine; Denis, Martine; de Valk, Henriette; Desenclos, Jean-Claude; Mégraud, Francis;

Published:

Feb 2007

Source:

Emerg Infect Dis. 13(2):259-266.

Description:

We describe isolates from human Campylobacter infection in the French population and the isolates' antimicrobial drug resistance patterns since 1986 and compare the trends with those of isolates from broiler chickens and pigs from 1999 through 2004. ...

File Type:

[PDF - 260.43 KB]
Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection

Personal Author:

Read, Tim R.H.; Jensen, Jørgen S.; Fairley, Christopher K.; Grant, Mieken; Danielewski, Jennifer A.; Su, Jenny; Murray, Gerald L.; Chow, Eric P.F.; Worthington, Karen; Garland, Suzanne M.; Tabrizi, Sepehr N.; Bradshaw, Catriona S.;

Published:

Feb 2018

Source:

Emerg Infect Dis. 24(2):328-335.

Description:

High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic...

File Type:

[PDF - 623.04 KB]
Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium

Personal Author:

Murray, Gerald L.; Bradshaw, Catriona S.; Bissessor, Melanie; Danielewski, Jennifer; Garland, Suzanne M.; Jensen, Jørgen S.; Fairley, Christopher K.; Tabrizi, Sepehr N.;

Published:

May 2017

Source:

Emerg Infect Dis. 23(5):809-812.

Description:

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region. Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S8...

File Type:

[PDF - 9.10 MB]
Comparison of Escherichia coli ST131 Pulsotypes, by Epidemiologic Traits, 1967–2009

Personal Author:

Johnson, James R.; Nicolas-Chanoine, Marie-Hélène; DebRoy, Chitrita; Castanheira, Mariana; Robicsek, Ari; Hansen, Glen; Weissman, Scott; Urban, Carl; Platell, Joanne; Trott, Darren; Zhanel, George; Clabots, Connie; Johnston, Brian D.; Kuskowski, Michael A.;

Corporate Author:

MASTER Investigators

Published:

Apr 2012

Source:

Emerg Infect Dis. 18(4):598-607.

Description:

Escherichia coli sequence type 131 (ST131), an emerging disseminated public health threat, causes multidrug-resistant extraintestinal infections. Among 579 diverse E. coli ST131 isolates from 1967-2009, we compared pulsotypes (>94% similar XbaI pulse...

File Type:

[PDF - 175.31 KB]